G92.01 Immune effector cell-associated neurotoxicity syndrome, grade 1

Name of the Condition

• Immune effector cell-associated neurotoxicity syndrome, grade 1

Summary

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological condition that can occur following treatment with certain immunotherapies, particularly those involving immune effector cells like CAR T-cells. It is characterized by a range of neurologic symptoms resulting from inflammation or toxicity to the central nervous system. The "grade 1" designation indicates mild severity, typically involving minimal or no impact on activities of daily living.

Causes

ICANS is caused by the release of inflammatory cytokines and immune-mediated damage to the brain and nervous system, typically triggered by immunotherapy treatments that activate immune cells to target cancer cells. The exact mechanisms involve cytokine release and potential direct neurotoxic effects.

Risk Factors

• Receipt of immunotherapy, especially CAR T-cell therapy or other immune effector cell treatments
• Underlying cancer type and disease burden
• Prior history of neurologic conditions or central nervous system involvement
• Concomitant use of other medications that may affect neurologic function

Symptoms

• Altered mental status or confusion
• Aphasia (difficulty speaking or understanding language)
• Tremors or asterixis (hand flapping)
• Seizures
• Headache
• Dizziness or ataxia (loss of coordination)
• Visual disturbances

Diagnosis

Diagnosis is based on clinical evaluation of neurologic symptoms in the context of recent immunotherapy. Grading follows standardized criteria (e.g., ASTCT consensus) to assess severity. Laboratory tests and neuroimaging may be used to rule out other causes, but clinical assessment is primary.

Treatment Options

• Supportive care, including monitoring and symptom management
• Corticosteroids for severe cases
• Adjustments to immunotherapy dosing or timing
• Antiseizure medications if seizures occur

Prognosis and Follow-Up

Most grade 1 cases resolve with supportive care and do not require treatment interruption. Recovery is typically rapid, but ongoing monitoring is recommended to detect progression. Follow-up should include regular neurologic assessments until symptoms resolve.

Complications

• Progression to higher grades of ICANS
• Prolonged neurologic symptoms
• Impact on cognitive function (rare in mild cases)

Lifestyle & Prevention

• Adherence to prescribed immunotherapy protocols
• Prompt reporting of new or worsening neurologic symptoms
• Avoidance of other medications that may exacerbate neurotoxicity unless medically necessary

When to Seek Professional Help

Seek immediate medical attention if symptoms worsen, new neurologic symptoms develop, or daily activities become impaired. Early intervention can prevent progression to more severe grades.

Tips for Medical Coders

Document the grade of ICANS (grade 1) and the context of immunotherapy treatment. Ensure clinical notes support the severity level and exclude other causes of neurologic symptoms. Code G92.01 is specific to grade 1; do not use for unspecified or higher grades.